Notice2026-05906

Notice Pursuant to the National Cooperative Research and Production Act of 1993-Biopharmaceutical Manufacturing Preparedness Consortium

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
March 26, 2026

Issuing agencies

Justice DepartmentAntitrust Division

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 58 (Thursday, March 26, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 58 (Thursday, March 26, 2026)]
[Notices]
[Pages 14715-14716]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-05906]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Biopharmaceutical Manufacturing Preparedness 
Consortium

    Notice is hereby given that, on October 8, 2025, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Biopharmaceutical 
Manufacturing Preparedness Consortium (``BIOMAP-CONSORTIUM'') has filed 
written notifications simultaneously with the Attorney General and the 
Federal Trade Commission disclosing changes in its membership. The 
notifications were filed for the purpose of extending the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances. Specifically, AGC Biologics, 
Bothell, WA; Anavatos Bio, Inc., Seattle, WA; Cidara Therapeutics INC, 
San Diego, CA; Crossmhv, L.l.C, Tampa, FL; Defense Operations & 
Execution Solutions INC, W Melbourne, FL; Health Supply US LLC, 
Mooresville, NC; Nanopass Technologies Ltd., Nes Ziona, STATE OF 
ISRAEL; Ommio Health, INC, Woodbridge, CT; UI Pharmaceuticals, Iowa 
City, IA; Axelyf, Inc., Chestnut Hill, MA; BetteRx Compounding Inc., 
Smithfield, RI; Crossject SA, Dijon, FRENCH REPUBLIC; Lavik Consulting 
LLC, Oakland, MO; Nanotag Biotechnologies Gmbh, Goettingen, FEDERAL 
REPUBLIC OF GERMANY; Quality Assured Artificial Intelligence LLC, Green 
Cove Springs, FL; Award Advisors, Washington, DC; Beckman Research 
Institute of the City of Hope, Duarte, CA; Gemini Therapeutics, San 
Fransisco, CA; Lumacyte, INC, Charlottesville, VA; Modus Operandi,

[[Page 14716]]

Inc., Melbourne, FL; Ship Odyssey, Inc., Sevierville, TN; Synergistic 
INC, New Baltimore, MI; Occam Systems Incorporated, Glen Allen, VA; 
Renco Manufacturing Group INC, Colebrook, NH; Revolution 
Biomanufacturing INC, Canton, MA; Sagitta Biotech, Li[egrave]ge, 
KINGDOM OF BELGIUM; Argentum Pharmaceuticals LLC, Aspen, CO; Culmen 
International, LLC, Alexandria, VA; EXCITE PHARMA SERVICES, LLC, Lees 
Summit, MO; Johns Hopkins Center for Health Security, Baltimore, MD; 
KNIGHT GREGORIAN, INC., Vista, CA; Kensington Street Consulting LLC, 
Arlington, VA; Method Made, Montreal, CANADA; Mriglobal, Kansas City, 
MO; N! Biomachines Ltd., Burlington, ON; Safi Biotherapeutics INC, 
Cambridge, MA; Science Systems and Applications, Inc., Lanham, MD; True 
Diagnostics, Inc., Carlsbad, CA; and Zeteo Biomedical LLC, Austin, TX 
have been added as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and the BIOMAP-CONSORTIUM intends to 
file additional written notifications disclosing all changes in 
membership.
    On January 5, 2024, the BIOMAP-CONSORTIUM filed its original 
notification pursuant to section 6(a) of the Act. The Department of 
Justice published a notice in the Federal Register pursuant to section 
6(b) of the Act on April 16, 2024 (89 FR 26923).
    The last notification was filed with the Department on July 24, 
2025. A notice was published in the Federal Register pursuant to 
section 6(b) of the Act on January 20, 2026 (91 FR 2369).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2026-05906 Filed 3-25-26; 8:45 am]
BILLING CODE P


</pre></body>
</html>
Indexed from Federal Register on March 26, 2026.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.